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Abstract
Background: Tuberculosis (TB) is the most common opportunistic infection in HIV-infected
adults in developing countries. Isoniazid (INH) is recommended for treatment of latent TB
infection, however non-adherence is common. The purpose of this study was to apply in-house
prepared isoniazid (INH) urine test strips in a clinical setting, and identify predictors of positive test
results in an adherence questionnaire in HIV-infected adults taking INH for prevention of TB.
Methods: Cross-sectional study of adherence using a questionnaire and urine test strips for
detection of INH metabolites at two hospitals in Pietermaritzburg, South Africa. Participants were
aged at least 18 years, HIV positive, and receiving INH for prevention of tuberculosis disease.
Univariate and multivariate analyses are used to identify factors relevant to adherence.
Results: 301 consecutive patients were recruited. 28% of participants had negative urine tests. 32
(37.2%, 95% CI25.4, 45.0) of the 86 patients who received INH from peripheral pharmacies said
the pharmacy had run out of INH at some time, compared with central hospital pharmacies (p =
0.0001). In univariate analysis, a negative test was associated with self-reported missed INH doses
(p = 0.043). Each 12-hour increment since last reported dose increased the likelihood of a negative
test by 34% (p = 0.0007). Belief in INH safety was associated with a positive test (p = 0.021). In
multivariate analysis, patients who believed INH is important for prevention of TB disease were
more likely to be negative (p = 0.0086).
Conclusion:  Adequate drug availability at peripheral pharmacies remains an important
intervention for TB prevention. Key questions may identify potentially non-adherent patients. In-
house prepared urine tests strips are an effective and cheap method of objectively assessing INH
adherence, and could be used an important tool in TB control programs.
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Background
Tuberculosis (TB) remains a major global epidemic
despite widespread awareness and effective prevention
and therapy. Human immunodeficiency virus (HIV)
infection has had a devastating effect on the TB epidemic.
In South Africa an estimated two million people are co-
infected, as are 60% of all patients with newly diagnosed
TB [1].
Accordingly, the World Health Organization and Ameri-
can Thoracic Society now recommend INH for treatment
of latent TB infection (LTBI) in HIV-infected patients who
are TST positive [2,3]. If skin testing is not feasible, INH is
still recommended in regions with high TB prevalence [2].
Studies have shown rates of non-adherence to be typically
8–33% [4-13]. One objective measure of adherence is a
biochemical test called the Arkansas method, where a
chemical reaction with urinary INH metabolites produces
a visible blue colour change [4,14,15]. This method has a
high sensitivity (>99%) and specificity (>96%) [4,7,15].
While commercial test strips are not readily available in
developing countries, they can be reproduced in-house at
very little cost, without compromising quality [6,15].
Compared to commercial test strips, in-house prepared
strips have a sensitivity and specificity of 99.5% and
96.4% respectively [6]. Their low cost, ease of use, and
accuracy make them an ideal evaluative component of TB
control programs.
The aim of our study was to apply in-house prepared INH
urine test strips in a clinical setting in HIV-infected adults
taking INH for prevention of TB, and to identify predictors
of positive urine test results in an adherence questionnaire
at two South African hospitals.
Methods
Setting
The study sample consisted of consecutive outpatients
from HIV clinics at two hospitals in Pietermaritzburg,
South Africa. Hospital A provides tertiary care and is
located in an affluent suburban area; attendees pay US $3
for a consultation or medication. Hospital B is a district
hospital in an impoverished suburban area, with limited
access to specialist care and significantly less modern facil-
ities. Patients may attend either hospital's HIV clinic; the
same physicians staff clinics at both sites. Few patients
were on antiretroviral therapy at the time of the study as
the anti-retroviral rollout had not yet occurred.
Patients fill their INH prescription at the hospital phar-
macy or at community pharmacies that are funded by the
provincial government.
Regular clinic attendees were asked to participate in the
study if they were 18 years or greater, HIV infected and
prescribed INH (300 mg daily) with pyridoxine for pre-
vention of TB. Clinic policy was not to perform TST prior
to initiating therapy, and to continue treatment indefi-
nitely. Patients receiving INH as part of multi-drug ther-
apy for active TB and those with frank hematuria were
excluded from the study. All participants gave written
informed consent. The questionnaire and urine test were
performed once in each patient with no follow up testing.
Procedures
Consecutive patients who met entry criteria were invited
to participate by a study nurse. For those accepting, a
nurse administered the questionnaire and performed the
urine test prior to their appointment with the physician.
One question asked participants to explain why they were
taking INH. A correct response was if they indicated the
INH was either to prevent or treat TB.
The preliminary questionnaire was developed from
review of previous studies of factors affecting adherence
[6-9,13,16-20]. Additionally relevant questions were sub-
sequently added after review by all the authors. The ques-
tionnaire was available in English or a translated Zulu
form depending on patient preference.
Test strips were prepared via the description by Kilburn et
al [15]. Filter paper [21] (cut into strips 6 × 0.8 cm) was
marked at one end with a graphite pencil. The following
stock solutions were prepared: 5% barbituric acid (pH
adjusted to 5.2 using 50% sodium hydroxide), 60%
potassium thiocyanate in 8% citric acid, and 50% chlo-
ramine T. Distilled water was the base medium in all solu-
tions. The barbituric acid and chloramine T solutions
were warmed prior to spotting to aid in solubilization.
Each strip was spotted with 25 µl in three separate bands,
with chloramine T and barbituric acid at the ends and
potassium thiocyanate in the middle. The barbituric acid
was spotted over the end of the strip previously marked;
the strips were then air-dried and stored. In the present
study, a single individual (TAS) made 500 test strips in
four hours. There were no special laboratory needs; only
the chemicals and standard lab equipment were required.
Each strip cost less than 1 US cent to prepare.
Midstream urine was collected in a standard urine bottle.
To detect INH, 0.5 ml of patient urine was pipetted from
the urine bottle into a test tube, a test strip was added and
a stopper applied. The strips were placed with the barbitu-
ric acid end downward. After one hour the urine and test
strip were read. Patients' urine was deemed positive (INH
metabolite present) if the urine or test strip turned a blue-
green to dark blue colour, and negative (no INH metabo-
lite present) if the urine and test strip remained yellow.BMC Infectious Diseases 2006, 6:97 http://www.biomedcentral.com/1471-2334/6/97
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Urine testing was performed just prior to the question-
naire. The questionnaire and urine test were completed on
each participant once, with no further follow up testing.
For the purpose of this study, patients were deemed to be
adherent or non-adherent based on the result of the urine
test. To ensure that the test strips were grossly effective,
prior to initiating patient recruitment, urine test strips
were pilot tested by 5 volunteers from the Department of
Medicine at Hospital A. Each volunteer took INH 300 mg
once, and had urine samples checked at time 0, 24, 36 and
72 hours. The color of the urine and test strip was
recorded.
This study is in compliance with the Helsinki Declaration
and received ethical approval from the Ottawa Hospital
Regional Ethics Board and the Research Ethics Commit-
tee, Nelson R. Mandela School of Medicine, University of
KwaZulu Natal.
Statistical analysis
Descriptive statistics were generated for the overall patient
population, including means and standard deviations for
continuous variables, and proportions and 95% confi-
dence limits for categorical variables. These statistics were
then calculated for each hospital. Means and proportions
were compared using t-tests and chi-square testing, respec-
tively. Exploratory analyses were conducted on variables
relevant to medication availability and provision in dis-
pensing pharmacies. Associations between variables and
urine test results (positive or negative) were assessed with
univariate and multivariate logistic regression analyses. In
multivariate analyses, a forward selection procedure was
used, beginning with variables that were found to be sig-
nificant predictors in univariate analyses. Variables were
entered into the model if p < 0.15, and taken out if p >
0.15. The model's overall fit to the data was assessed with
Hosmer and Lemeshow goodness-of-fit testing. All of the
above analyses were conducted using SAS 8 statistical soft-
ware (SAS Institute, Cary, NC, USA).
Results
During the urine test strip pilot testing by 5 volunteers, all
samples were positive at 24 hours, and became negative at
72 hours, consistent with the expected pattern.14 The indi-
vidual results of the tests are shown in Additional file 1.
Between February and May 2004, 304 consecutive
patients meeting entry criteria were identified. Consent
was obtained from 301 of these patients, while 3 patients
refused to participate. All of the questionnaire items and
their responses are shown in Additional file 2. The full
English version of the questionnaire is shown in Addi-
tional file 3.
The mean age of study participants was 35, with 76.7%
being female. Each household had an average of 6.3 peo-
ple and a total monthly income of US $238. The mean
duration since HIV diagnosis was 33.3 months (SD 26)
and mean time on INH therapy was 18.7 months (SD 17).
On average, participants had told 3.0 people they were
taking INH and 3.1 people that they have HIV, while a
substantial portion (20.7% and 17.3% respectively) had
not told anyone. A total of 18 patients (6%) were on anti-
retrovirals.
Overall, 28.0% of urine tests were negative. There was no
significant difference in urine results between the two hos-
pitals; however, there were a number of qualitative differ-
ences (see Additional file 2). In particular, there was
considerable variation in where study participants get
their INH. At Hospital A only 4 patients (4.0%, 95% CI
0.2, 7.9) attended peripheral pharmacies, while the
remainder attended the hospital pharmacy. In contrast, at
Hospital B, 86 patients (42.8%, 95% CI 35.9, 49.6)
attended peripheral pharmacies. For patients getting their
INH at Hospital A, 42.1% (95% CI 32.2, 52.0) said they
sometimes could not afford to go to the pharmacy. This
occurred in only 3.5% (95% CI 0.001, 0.0069) attending
the Hospital B pharmacy, and 1.1% attending peripheral
pharmacies (χ2 = 80.3, p = 0.0001). The proportion of
patients who ran out of INH between hospital visits was
7.3%, 19.3%, and 26.4%, among patients receiving INH
from Hospital A, Hospital B, and peripheral pharmacies,
respectively (χ2 = 12.1, p = 0.0024). Only 1 patient at Hos-
pital B and none at Hospital A reported their pharmacy
had previously run out of INH. However, this occurred for
32 patients (37.2%, 95% CI 25.4, 45.0) attending periph-
eral pharmacies (χ2 = 78.3, p = 0.0001). Participants
attended 25 different peripheral pharmacies; 8 of these
serviced 73 of the total 86 patients (80.2%). No particular
pharmacy was statistically associated with urine test
results; however 41.1% of patients attending these 8 phar-
macies said it had run out of medications at some time. At
the most frequented pharmacy, 10 of 18 patients (55.6%)
reported this had occurred.
In univariate logistic regression analysis, three factors
were found to have a statistically significant impact on
urine test results (Table 1). Longer time since last self-
reported INH dose showed a stepwise increase in proba-
bility of having a negative urine test (OR 1.33; 95% CI,
1.13 to 1.57; p = 0.0007). This relationship is shown in
Figure 1. Every 12-hour increase in reported time resulted
in a 34% (95% CI 13%, 57%) increase in the probability
of a negative urine test. Those who believed the INH was
safe were less likely to have a negative urine test (OR 0.47;
95% CI, 0.25 to 0.90; p = 0.021). There was also a non-
significant trend towards increased compliance in those
who believed INH was not safe (OR 0.71; 95% CI, 0.29 toBMC Infectious Diseases 2006, 6:97 http://www.biomedcentral.com/1471-2334/6/97
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1.75; p = 0.45). Finally, patients who reported they some-
times forget to take the INH were more likely to have neg-
ative tests (OR 2.0; 95% CI, 1.02–3.99; p = 0.043).
Time since last reported INH dose and probability of a
negative test remained unchanged in all multivariate anal-
yses (Table 2). As well, belief that INH is safe continued to
decrease the likelihood of a negative urine test (p =
0.0098). Overall, only nine patients in the study answered
that their chance of getting TB without INH were average
or below average. Those who felt their chances of getting
sick from TB without INH were above average or high
were more likely to have negative urine results, when
compared to those who didn't know (OR 3.00; 95% CI,
1.32 to 6.79; p = 0.0086). The variable of patient forget-
fulness in taking the INH was not found to be significant
in the multivariate analysis.
Discussion
Urine testing measured the overall rate of non-adherence
at 28%. This is similar to other studies that have shown
rates varying between 8–33% [4-13]. However, there are
few consistent predictors of adherence between studies.
Some show that homelessness, alcoholism, adherence
counselling, race, prior BCG, sex, and age had significant
influences [7,8,13,16-18]. Others point to social factors
[19,20], and still others have found no correlative factors
[5,6]. In the present study a number of predictive factors
were found, including the self reported time since last
INH dose. When asked how frequently they take the INH,
Table 1: Univariate logistic regression analyses of study variables showing a significant association with a negative urine test result
Variable OR (95% CI) p value
How long since last INH dose? (12-hour 
increments)?
1.33 (1.13, 1.57) 0.0007
Statement: INH is dangerous to your health
Strongly agree/agree 0.71 (0.29, 1.75) 0.45
Disagree/strongly disagree 0.47 (0.25, 0.90) 0.021
Don't know 1.00
Do you ever forget to take INH? 2.0 (1.02, 3.99) 0.043
Urine result based on time since last self-reported INH dose (95% CI shown in bars) Figure 1
Urine result based on time since last self-reported INH dose (95% CI shown in bars).
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95.3% of participants said daily, reflecting their under-
standing that INH should be taken daily. If broadly asked
about adherence in judgmental or threatening contexts,
one may not be straightforward. However, a less threaten-
ing question, such as time since last dose is valid in com-
parison with urine testing. Use of 12-hour time
increments provides an easy estimate of the probability of
a negative urine test. This confirms the same relationship
that was found in a study of LTBI by Perry et al [8].
Patients who report they sometimes forget to take their
medication were more likely to have a negative urine test.
This was previously identified as a predictor in another
study of patients on INH for LTBI [9]. There, 33% admit-
ted to forgetting to take the INH, while this occurred in
14% of our study.
Those who expressed any opinion as to the safety of INH
were less likely to test negative (i.e., more likely adherent
to therapy). Participants who disagreed that INH was a
danger to their health were significantly less likely to test
negative in univariate and multivariate analyses, than
those who stated they did not know. However, it is inter-
esting that those who agreed that INH is dangerous were
also less likely to test negative, without statistical signifi-
cance. This may reflect the small number of respondents
who "strongly agreed" or "agreed" with the statement
(1.7% and 8.7% of respondents, respectively), or may rep-
resent lack of understanding of the question.
Patients were on INH for an average of 18.7 months,
longer than the typical 6–12 month course [2,3]. In Pie-
termaritzburg, longer therapy is used as primary and sec-
ondary prophylaxis to prevent new infection from
ongoing exposure. Although this contrasts to current
international guidelines, there are studies supporting this
approach [22-24]. One study in South Africa examined
indefinite secondary therapy in HIV-infected patients with
prior active TB and found a 55% reduction in the inci-
dence of TB recurrence [22].
Unlike other studies where INH side effects impacted
adherence [7,13,16] we did not find this relationship. In
fact, only 6% reported this, compared to up to 74% in
other studies [13]. While this may be due to selection of
patients that had been able to tolerate INH for a pro-
longed time, univariate and multivariate testing did not
find that duration of treatment affected adherence.
In multivariate analysis, those believing they have a high
or above average chance of getting active TB without INH
were more likely non-adherent. While this seems paradox-
ical, it might be explained by social factors. Patients may
perceive stigma or conceal their condition and its treat-
ment, which could interfere with adherence. Alternatively,
knowledge of the danger of TB may motivate them to
share or sell their INH to others who are also at risk. As
this relationship is counter-intuitive it merits further
study.
To our knowledge, ours is the first study to identify loca-
tion of drug supply as a factor in adherence. An alarming
number of peripheral pharmacies are reported to run out
of medications, which may impair overall adherence.
Although pharmacy location did not significantly impact
urine test results, the study was not designed to detect this
difference. Regardless, this identification of impaired
access to medicines may represent an important barrier to
overall adherence.
In areas where patients attend peripheral pharmacies, TB
programs should include resources to routinely audit and
address supply problems. Alternatively, it may be neces-
sary to subsidize or facilitate transportation to hospital
pharmacies. These conclusions have additional relevance
in the context of the South African antiretroviral rollout,
Table 2: Multivariate logistic regression model of study variables predicting a negative urine test result
Variable Parameter estimate OR (95% CI) p value
Intercept -1.84 0.0064
How long since last INH dose? 
(12-hour increments)?
0.30 1.34 (1.13, 1.59) 0.0007
Statement: INH is dangerous to 
your health
Strongly agree/agree -0.48 0.62 (0.21, 1.81) 0.38
Disagree/strongly disagree -1.08 0.34 (0.15, 0.77) 0.0098
Don't know 0 1.00
Statement: Without INH, your 
chance of getting sick from TB is:
High/above average 1.10 3.00 (1.32, 6.79) 0.0086
Average/below average 0.96 2.61 (0.49, 13.8) 0.26
Don't know 0 1.00
Goodness-of-fit statistic = 4.28 (p = 0.83)BMC Infectious Diseases 2006, 6:97 http://www.biomedcentral.com/1471-2334/6/97
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which ultimately will be delivered by primary health care
facilities.
To our knowledge, only the present study and that by
Meissner et al [6] have applied in-house prepared test
strips. However, in our study we identified qualitative
issues not described previously. Only when the barbituric
acid end was placed in the urine would the reaction pro-
ceed appropriately, hence that end was marked with a
pencil. Otherwise, strips with the chloramine T end down-
ward were uniformly negative. Also, previous studies say
results were available within 10–15 minutes [6,15]. While
this was true for the majority, we found a small portion of
results remained ambiguous, and when we extended the
evaluation time to one hour some samples then became
more clearly positive.
Some factors may have an impact on use of the urine test.
The rate of INH metabolism is affected by liver acetylator
status, with some patients exhibiting rapid drug metabo-
lism. No study has attempted to address the impact of this
status on the urine test results. Also, there are conflicting
reports on impaired INH absorption in HIV and TB co-
infection [25-27]. Lastly, it may seem attractive to extrap-
olate the urine test for assessing compliance in patients
with active tuberculosis receiving multi-drug therapy.
However, no study has formally examined the biochemi-
cal impact that other anti-tuberculosis medications may
have on urine testing for INH metabolites.
Although the urine test is a single point measurement and
does not necessarily reflect overall adherence, its bio-
chemical characteristics make it a useful predictor. 48
hours after the last dose 76% of patients will have a posi-
tive result, while after 72 hours only 6% will remain pos-
itive [14]. In fact, one study showed that urine testing is an
accurate estimate of overall adherence when compared to
electronic monitoring of pill-bottle lid opening [28].
Another study performed random urine testing between
scheduled appointments and found similar rates of adher-
ence between visits as at appointments [9]. So, urine test-
ing may give a realistic estimate of overall adherence and
is not necessarily affected prior to clinic visits due to a
"white coat effect".
Conclusion
Commercially available test strips use the same reaction
but are expensive and difficult to acquire, while in-house
prepared strips are easily produced and at very little cost.
As the procedure is readily reproduced, thousands of
strips could be routinely made to meet the testing needs
of a given clinic population without significant time or
cost.
Monitoring and enhancement of adherence should be
part of TB treatment and control programs. In-house pre-
pared urine test strips are inexpensive, effective and rapid,
and could be used as a major evaluative tool in TB control
programs.
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